Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.66)
# 548
Out of 5,329 analysts
90
Total ratings
55.88%
Success rate
35.35%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics | Upgrades: Outperform | 60 99 | 38.55 | 156.81% | 2 | Feb 14, 2025 | |
TVTX Travere Therapeutics | Maintains: Outperform | 33 45 | 21.02 | 114.08% | 5 | Feb 12, 2025 | |
BCRX BioCryst Pharma | Maintains: Outperform | 10 12 | 8.91 | 34.68% | 5 | Jan 13, 2025 | |
EDIT Editas Medicine | Maintains: Outperform | 7 5 | 1.67 | 199.4% | 5 | Dec 16, 2024 | |
CARM CARISMA Therapeutics | Downgrades: In-Line | 4 1 | 0.23 | 204.35% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 7 5 | 3.4 | 47.06% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 35 | 27.83 | 25.76% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 405 360 | 316.46 | 13.76% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 210 260 | 258.97 | 0.4% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 945 70 | 2.68 | 2511.94% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: In-Line | 7 2 | 1.21 | 65.29% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 33 | 8.71 | 278.87% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 38 | 45.05 | -15.65% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 438 | 502.12 | -12.77% | 15 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 60 80 | 39.55 | 102.28% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 18 | 5.37 | 235.2% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 25 | 5.88 | 325.17% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 62 | 6.05 | 924.79% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 6.24 | 460.9% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 24 | 24.81 | -3.26% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 378 | n/a | n/a | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Outperform | 30 | 10.38 | 189.02% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 10 | 3.6 | 177.78% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 175 | n/a | n/a | 3 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 10 16 | n/a | n/a | 1 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | n/a | n/a | 1 | May 19, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 31, 2017 |